title: Assessment of baseline clinical predictive factors of response to cetuximab-irinotecan in patients with irinotecan-refractory metastatic colorectal cancer.
abstract: OBJECTIVE
  To identify easily available predictive factors of response to cetuximab-irinotecan in patients with irinotecan-refractory metastatic colorectal cancer.
  
  
  METHODS
  Retrospective analysis of patients treated with cetuximab (400 mg/m(2) in week 1, 250 mg/m(2) in subsequent weeks) plus irinotecan (180 mg/m(2) every 2 weeks). We assessed demographic data, prior response to chemotherapy, number of metastatic sites, disease and metastatic disease durations, irinotecan-free interval and tumoral immunohistochemical epidermal growth factor receptor status.
  
  
  RESULTS
  We analyzed 311 patients. Objective response rate under cetuximab-irinotecan was 26%. In univariate analysis, prior response to irinotecan, presence of only 1 metastatic site, disease duration, metastatic disease duration and irinotecan-free interval equal or above median (24, 18 and 1.8 months, respectively) were predictive of response to cetuximab-irinotecan. Multivariate analysis confirmed independent predictive value of prior response to irinotecan, number of metastatic sites and disease duration.
  
  
  CONCLUSIONS
  Prior response to irinotecan, number of metastatic sites and disease duration may contribute to better select patients suitable for cetuximab-irinotecan therapy.
authors.affiliation: Medical Oncology Unit, University Hospital, Lille, France. m-hebbar@chru-lille.fr
authors.forename: Mohamed
authors.initials: M
authors.lastname: Hebbar
authors.forename: Frédéric
authors.initials: F
authors.lastname: Di Fioré
authors.forename: Thierry
authors.initials: T
authors.lastname: Conroy
authors.forename: Claire
authors.initials: C
authors.lastname: Giraud
authors.forename: Laurent
authors.initials: L
authors.lastname: Gasnault
authors.forename: Charles
authors.initials: C
authors.lastname: Fournier
authors.forename: Renata
authors.initials: R
authors.lastname: Péreira
authors.forename: Olivier
authors.initials: O
authors.lastname: Bouché
authors.forename: Peggy
authors.initials: P
authors.lastname: Fournier
authors.forename: Nathalie
authors.initials: N
authors.lastname: Deligny
authors.forename: Jean-Paul
authors.initials: JP
authors.lastname: Joly
authors.forename: Patricia
authors.initials: P
authors.lastname: Maes
authors.forename: Emilia
authors.initials: E
authors.lastname: Rad
authors.forename: Pierre
authors.initials: P
authors.lastname: Michel
authors.forename: Antoine
authors.initials: A
authors.lastname: Adenis
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy* / Q000556:secondary; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000911:Antibodies, Monoclonal / Q000008:administration & dosage; D061067:Antibodies, Monoclonal, Humanized; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002166:Camptothecin / Q000008:administration & dosage / Q000031:analogs & derivatives; D000068818:Cetuximab; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000473:pathology; D019008:Drug Resistance, Neoplasm; D066246:ErbB Receptors / Q000378:metabolism; D005260:Female; D006801:Humans; D007124:Immunoenzyme Techniques; D000077146:Irinotecan; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D012189:Retrospective Studies; D016879:Salvage Therapy; D015996:Survival Rate; D016896:Treatment Outcome
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000077146:Irinotecan; D066246:ErbB Receptors; D000068818:Cetuximab; D002166:Camptothecin